Natural Killer Cell Lymphomas is an indication for drug development with over 70 pipeline drugs currently active. According to GlobalData, preregistered drugs for Natural Killer Cell Lymphomas have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Natural Killer Cell Lymphomas compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Natural Killer Cell Lymphomas overview
Natural killer (NK) cell lymphomas are a rare and aggressive type of lymphoma arising from a subset of white blood cells called natural killer cells, which are part of the body’s immune system. These lymphomas can affect various organs and tissues in the body. NK cell lymphomas are categorized into two main types. Extranodal NK/T-cell lymphoma, nasal type (ENKTL) is a subtype that primarily affects the upper respiratory tract, particularly the nasal cavity and sinuses. ENKTL is more prevalent in certain geographical areas, particularly in East Asia and Central/South America. It is associated with the Epstein-Barr virus (EBV) in many cases. Aggressive NK cell leukemia is a rare and highly aggressive form of leukemia where abnormal NK cells proliferate in the blood and bone marrow, leading to a rapid progression of symptoms. Symptoms of NK cell lymphomas vary depending on the location and stage of the disease but can include fever, enlarged lymph nodes, nasal congestion or ulceration (in the case of ENKTL), skin lesions, night sweats, weight loss, and overall deterioration in health.
For a complete picture of PTSR and LoA scores for drugs in Natural Killer Cell Lymphomas, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
